Sabby Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sabby Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,638	Closed	-$31.3M	–	313
2016 Q4	$31.3M	Buy	+8,638	New	+$345K	1.82%	14
2016 Q3	–	Sell	-3,618	Closed	-$18.2M	–	337
2016 Q2	$18.2M	Buy	+3,618	New	+$193K	0.95%	20
2015 Q3	–	Sell	-54	Closed	-$319K	–	401
2015 Q2	$319K	Sell	54 -10,284	-99%	-$634K	0.01%	276
2015 Q1	$64.4M	Buy	10,338 +9,922	+2,385%	+$577K	2.68%	8
2014 Q4	$2.39K	Sell	416 -628	-60%	-$35K	0.08%	112
2014 Q3	$5.61K	Sell	1,044 -5,826	-85%	-$309K	0.22%	61
2014 Q2	$36M	Sell	6,870 -8,322	-55%	-$425K	1.54%	14
2014 Q1	$80.3M	Buy	15,192 +14,525	+2,178%	+$671K	4.5%	4
2013 Q4	$2.67M	Hold	667	–	–	0.17%	69
2013 Q3	$2.52M	Sell	667 -446	-40%	-$17.4K	0.16%	70
2013 Q2	$4.36M	Buy	+1,113	New	+$43.3K	0.29%	67

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's TEVA Position: Q3 2015 in Review

Sabby Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 4,173 shares — an estimated $247K sold.

Sabby Management first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $53.1M in Q2 2014. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Sabby Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Sabby Management sold 4,173 Teva Pharmaceuticals shares in Q3 2015, an estimated $247K.
Sabby Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Sabby Management's Teva Pharmaceuticals position peaked at $53.1M in Q2 2014.
824 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.